

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMXG1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS	29	AUG 30	CA/CAPLUS - Increased access to 19th century research documents
NEWS	30	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:15:29 ON 07 SEP 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:15:39 ON 07 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 SEP 2005 HIGHEST RN 862534-94-9

DICTIONARY FILE UPDATES: 6 SEP 2005 HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical Data\10533077\compound.str



chain nodes :

10 11 12

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18

chain bonds :

8-10 10-11 10-12 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

5-7 6-9 7-8 8-9 8-10 10-11 10-12

exact bonds :

12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> s l1 sss full

FULL SEARCH INITIATED 11:15:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2552 TO ITERATE

100.0% PROCESSED 2552 ITERATIONS

2382 ANSWERS

SEARCH TIME: 00.00.01

L2 2382 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 11:16:03 ON 07 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l2

L3 4437 L2

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)
AND IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)

0 FENOCTIME

61237 "OLEIC"

4030191 "ACID"

52124 "OLEIC ACID"

("OLEIC" (W) "ACID")

7807 CATECHIN

19 SCOPADULCIOL

74 PENTAGALLOYL

333 BUFALIN

1157 BAFILOMYCIN

301 CONCANAMYCIN

19865 IGE

5 ALLERG

28236 ASTHMA

2027 URTICARIA

10736 ANAPHYLAXIS

5122 RHINITIS

523 BRONCHIECTASIS

15489 DERMATITIS

15736 MALARIA

L4 0 L3 AND (FENOCTIME OR "OLEIC ACID" OR CATECHIN OR SCOPADULCIOL
OR PENTAGALLOYL OR BUFALIN OR BAFILOMYCIN OR CONCANAMYCIN) AND
IGE AND ALLERG AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS
OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and and ige and allerg and (asthma or urticaria or anaphylaxis or rhinitis
or bronchiectasis or dermatitis or malaria)

MISSING TERM 'AND AND'

The search profile that was entered contains a logical
operator followed immediately by another operator.

=> s l3 and ige and allerg and (asthma or urticaria or anaphylaxis or rhinitis or
bronchiectasis or dermatitis or malaria)

19865 IGE

5 ALLERG

28236 ASTHMA

2027 URTICARIA

10736 ANAPHYLAXIS

5122 RHINITIS

523 BRONCHIECTASIS

15489 DERMATITIS

15736 MALARIA

L5 0 L3 AND IGE AND ALLERG AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS

OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and ige and allerg? and (asthma or urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)

19865 IGE
62330 ALLERG?
28236 ASTHMA
2027 URTICARIA
10736 ANAPHYLAXIS
5122 RHINITIS
523 BRONCHIECTASIS
15489 DERMATITIS
15736 MALARIA

L6 4 L3 AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl or bufalin or bafilomycin or concanamycin) and ige and allerg? and (asthma or urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)

0 FENOCTIME
61237 "OLEIC"
4030191 "ACID"
52124 "OLEIC ACID"
("OLEIC" (W) "ACID")
7807 CATECHIN
19 SCOPADULCIOL
74 PENTAGALLOYL
333 BUFALIN
1157 BAFILOMYCIN
301 CONCANAMYCIN
19865 IGE
62330 ALLERG?
28236 ASTHMA
2027 URTICARIA
10736 ANAPHYLAXIS
5122 RHINITIS
523 BRONCHIECTASIS
15489 DERMATITIS
15736 MALARIA

L7 1 L3 AND (FENOCTIME OR "OLEIC ACID" OR CATECHIN OR SCOPADULCIOL OR PENTAGALLOYL OR BUFALIN OR BAFILOMYCIN OR CONCANAMYCIN) AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> d bib abs

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
 TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI KR 2002-67653 A 20021102
 KR 2003-75511 A 20031028

AB The invention discloses a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.

=> s 16

19865 IGE
 62330 ALLERG?
 28236 ASTHMA
 2027 URTICARIA
 10736 ANAPHYLAXIS
 5122 RHINITIS
 523 BRONCHIECTASIS
 15489 DERMATITIS
 15736 MALARIA

L8 4. L3 AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)


=> d 1-4 bib abs hitstr

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:834661 CAPLUS
 DN 142:348646
 TI Recurrent **anaphylaxis** linked to pantoprazole
 AU Kollmeier, Alexa P.; Eddleston, Jane; Zuraw, Bruce L.; Christiansen, Sandra C.
 CS Department of Asthma, Allergy and Immunol., Scripps Clin., La Jolla, CA, 92037, USA
 SO Journal of Allergy and Clinical Immunology (2004), 114(4), 975-977
 CODEN: JACIBY; ISSN: 0091-6749
 PB Elsevier Inc.
 DT Journal
 LA English
 AB The case of a 47-yr-old man with recurrent **anaphylaxis** induced by pantoprazole, a benzimidazole proton pump inhibitor, is presented. In this patient, the pos. skin test response and increased tryptase level are consistent with prior case reports of proton pump inhibitor **anaphylaxis** and suggest an immediate hypersensitivity mechanism. Although mutations in the CYP2C19 gene were not identified, the timing of anaphylactic events invokes the possible involvement of modifying pharmacogenetic factors, variations in relative levels of drug-specific IgE, or both.
 IT 102625-70-7, Pantoprazole 138786-67-1, Protonix
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(recurrent **anaphylaxis** linked to pantoprazole)


RN 102625-70-7 CAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 138786-67-1 CAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:412815 CAPLUS

DN 140:386032

TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor

IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee

PA S. Korea

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI KR 2002-67653 A 20021102

KR 2003-75511 A 20031028


AB The invention discloses a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound

having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.

IT 73590-58-6, Omeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 117976-89-3, Rabeprazole
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazolic compound with proton pump inhibitor activity for preventing secretion of IgE-dependent histamine releasing factor)


RN 73590-58-6 CAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102625-70-7 CAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-45-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 117976-89-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:223222 CAPLUS
 DN 137:257592
 TI T-cell reactions to drugs in distinct clinical manifestations of drug
allergy
 AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner
 J.
 CS Division of Allergology, Clinic of Rheumatology and Clinical
 Immunology/Allergology, Inselspital, Bern, Switz.
 SO Journal of Investigational Allergology and Clinical Immunology (2001),
 11(4), 275-284
 CODEN: JIAIEF; ISSN: 1018-9068
 PB Hogrefe & Huber Publishers
 DT Journal
 LA English
 AB Recent data indicate that T cells play a major role in different forms of
 drug **allergies**. To show that T-cell reactions are involved in
 various forms of adverse reactions to different kinds of drugs, and that
 lymphocyte transformation and skin tests may be pos. in patients who had
 distinct clin. manifestations of drug **allergies**. We collected
 data of 44 patients with a highly suggestive history for adverse drug
 reaction who had on subsequent investigations a pos. lymphocyte
 transformation test. In 41/44 patients (93%) skin tests with the
 suspected drugs were performed and in some cases drug-specific **IgE**
 -antibodies were determined All patients were HLA typed. Clin. manifestations
 of the drug **allergy** were heterogeneous, comprising maculopapular
 and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum
 sickness, **urticaria**, as well as involvement of internal organs.
 Maculopapular exanthemas formed the largest group (54%), followed by
 reactions more indicative of immediate hypersensitivity (28%), such as
urticaria/angioedema. In most cases (63%), β -lactam
 antibiotics were found to have caused the **allergic** reaction.
 Skin tests for immediate reactions were pos. in 6/40 patients (15%)
 tested, those for late reactions in 24/38 patients (63%) tested. Our data
 provide evidence that drug-specific T cells can be detected in distinct
 clin. manifestations of drug **allergy**. A combined approach using
 a detailed case history, lymphocyte transformation tests, skin tests
 (immediate and delayed type) appears to be helpful to identifying the
 incriminated drug.
 IT 103577-45-3, Agopton
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (T-cell reactions to drugs in distinct clin. manifestations of drug
allergy)
 RN 103577-45-3 CAPLUS
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-
 pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:125206 CAPLUS
DN 137:210620
TI TU-572, a Potent and Selective CD45 Inhibitor, Suppresses IgE
-Mediated **Anaphylaxis** and Murine Contact Hypersensitivity
Reactions
AU Hamaguchi, Takuya; Takahashi, Akiko; Manaka, Akira; Sato, Masakazu; Osada,
Hiroyuki
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd.,
Saitama-shi, Japan
SO International Archives of Allergy and Immunology (2001), 126(4), 318-324
CODEN: IAAIEG; ISSN: 1018-2438
PB S. Karger AG
DT Journal
LA English
AB Background: CD45, receptor-type protein tyrosine phosphatases (PTPases)
are essential components of signaling through both the T cell receptor and
the B cell antigen receptor. However, the functional significance of CD45
in the signaling pathway through the high-affinity Ig (Ig) E receptor has
not yet been established. In this study, we demonstrate that the potent
CD45 inhibitor neg. regulates IgE-dependent **anaphylaxis**
and contact hypersensitivity reactions. Method: We have previously found
that TU-572, 2-[(4-methylthiopyridin-2-yl)methylsulfinyl]-5-
isopropoxybenzimidazole, had a potent and selective inhibitory effect
against PTPase activity of CD45. Using a CD45 inhibitor, we examined in
vitro and in vivo IgE-mediated responses. Results: TU-572
potently inhibited histamine release from rat peritoneal mast cells and
mouse systemic **anaphylaxis** reaction using monoclonal
anti-dinitrophenyl (DNP) IgE and DNP-BSA. TU-572 also
suppressed the immediate-type hypersensitivity response induced by
repeated epicutaneous application of trinitrochlorobenzene in BALB/c mice.
Conclusion: These findings revealed that the PTPase activity of CD45
played a critical role in signal transduction of IgE-mediated
anaphylaxis in vitro and in vivo. PTPase inhibitors such as
TU-572 are useful in the treatment of **allergic** diseases.
IT 326592-39-6, TU 572
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(TU-572, a potent and selective CD45 inhibitor, suppresses IgE
-mediated **anaphylaxis** and murine contact hypersensitivity
reactions)
RN 326592-39-6 CAPLUS
CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-
pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	145.98	307.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

FILE 'STNGUIDE' ENTERED AT 11:22:08 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 2, 2005 (20050902/UP).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	307.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 11:22:59 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L9 4437 L2

=> s wo2004041280/pn

L10 1 WO2004041280/PN
 (WO2004041280/PN)

=> sel rn

E1 THROUGH E17 ASSIGNED

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          3.32      310.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                                ENTRY      SESSION
CA SUBSCRIBER PRICE          0.00      -3.65
```

FILE 'REGISTRY' ENTERED AT 11:24:49 ON 07 SEP 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 SEP 2005 HIGHEST RN 862534-94-9
 DICTIONARY FILE UPDATES: 6 SEP 2005 HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> s el-el7
1 102625-70-7/BI
  (102625-70-7/RN)
1 103577-45-3/BI
  (103577-45-3/RN)
1 112-80-1/BI
  (112-80-1/RN)
1 117976-89-3/BI
  (117976-89-3/RN)
1 136565-26-9/BI
  (136565-26-9/RN)
1 151499-39-7/BI
  (151499-39-7/RN)
1 154-23-4/BI
  (154-23-4/RN)
1 4091-50-3/BI
  (4091-50-3/RN)
1 465-21-4/BI
  (465-21-4/RN)
1 50-00-0/BI
  (50-00-0/RN)
```

```

1 50-78-2/BI
  (50-78-2/RN)
1 50678-27-8/BI
  (50678-27-8/RN)
1 51-17-2/BI
  (51-17-2/RN)
1 51-45-6/BI
  (51-45-6/RN)
1 69365-65-7/BI
  (69365-65-7/RN)
1 73590-58-6/BI
  (73590-58-6/RN)
1 80890-47-7/BI
  (80890-47-7/RN)
L11 17 (102625-70-7/BI OR 103577-45-3/BI OR 112-80-1/BI OR 117976-89-3/
      BI OR 136565-26-9/BI OR 151499-39-7/BI OR 154-23-4/BI OR 4091-50
      -3/BI OR 465-21-4/BI OR 50-00-0/BI OR 50-78-2/BI OR 50678-27-8/B
      I OR 51-17-2/BI OR 51-45-6/BI OR 69365-65-7/BI OR 73590-58-6/BI
      OR 80890-47-7/BI)

```

=> d1-17

D1-17 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> d 1-17

```

L11 ANSWER 1 OF 17  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   151499-39-7  REGISTRY
ED   Entered STN:  01 Dec 1993
CN   Bafilomycin (9CI)  (CA INDEX NAME)
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2,
      USPATFULL

```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

63 REFERENCES IN FILE CA (1907 TO DATE)


2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```

L11 ANSWER 2 OF 17  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   136565-26-9  REGISTRY
ED   Entered STN:  04 Oct 1991
CN   9,11a-Methano-11aH-cyclohepta[a]naphthalen-8(9H)-one, 5-
      (benzoyloxy)dodecahydro-4-(hydroxymethyl)-4,9,11b-trimethyl-,
      (4R,4aR,5R,6aS,9S,11aS,11bS) - (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   9,11a-Methano-11aH-cyclohepta[a]naphthalen-8(9H)-one, 5-
      (benzoyloxy)dodecahydro-4-(hydroxymethyl)-4,9,11b-trimethyl-,
      [4R-(4α,4aa,5β,6aβ,9β,11aβ,11bβ)] -
OTHER NAMES:
CN   Scopadulciol
MF   C27 H36 O4
SR   CA
LC   STN Files:   ADISINSIGHT, AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, IPA,
      MEDLINE, TOXCENTER
      (*File contains numerically searchable property data)


```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN 117976-89-3 REGISTRY
ED Entered STN: 16 Dec 1988
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[[[3-Methyl-4-(3-methoxypropoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole
CN LY 307640
CN Pariets
CN Rabeprazole
FS 3D CONCORD
MF C18 H21 N3 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


464 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
466 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN 103577-45-3 REGISTRY
ED Entered STN: 02 Aug 1986
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-

pyridinyl)methyl)sulfinyl]-. (9CI) (CA INDEX NAME)

OTHER NAMES:


CN (+)-Lansoprazole
CN 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl]-1H-benzimidazole
CN A 65006
CN AG 1749
CN Agopton
CN Ilsatec
CN Ketian
CN Lancid
CN Lanfast
CN Lanproton
CN Lansopep
CN Lansophed
CN Lansoprazole
CN Lansox
CN Lanston
CN Lanz
CN Lanzol 30
CN Lanzopral
CN Lanzor
CN Lapraz
CN Ogast
CN Ogastro
CN PP/K-10
CN Prevacid
CN Promp
CN Prosogan
CN Suprecid
CN Takepron
CN Ulpax
CN Zoton
FS 3D CONCORD
DR 154727-72-7
MF C16 H14 F3 N3 O2 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1246 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1251 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 14 Jun 1986
 CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
 CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
 CN BY 1023
 CN Pantoprazole
 CN Pantozol
 CN SKF 96022
 FS 3D CONCORD
 DR 154644-14-1
 MF C16 H15 F2 N3 O4 S
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


645 REFERENCES IN FILE CA (1907 TO DATE)
 20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 649 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 80890-47-7 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Oxacyclooctadeca-3,5,13,15-tetraen-2-one, 18-[(1S,2R,3S)-3'-[(2R,4R,5S,6R)-4-[[4-O-(aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyl-, (3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Concanamycin A
 CN Oxacyclooctadecane, concanamycin A deriv.
 OTHER NAMES:
 CN Antibiotic X 4357B
 CN Concanamycin
 CN X 4357B
 CN [7R-[3Z,5E,7R*,8R*,9S*,10S*,11R*,13E,15E,17S*,18R*[1S*,2R*,3S*[2R*,4R*,5S*,6R*(E)]]]-18-[3-[4-[4-O-(Aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1-propenyl)-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyloxacyclooctadeca-3,5,13,15-tetraen-2-one


FS STEREOSEARCH
 DR 66771-59-3
 MF C46 H75 N O14
 CI COM
 LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, RTECS*, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 103 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 73590-58-6 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Benzimidazole, 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN (±)-Omeprazole
 CN 2-[[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole

CN 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-
 benzimidazole
 CN Acidex
 CN Antra
 CN Antra MUPS
 CN Audazol
 CN Aulcer
 CN Belmazol
 CN Ceprandal
 CN Desec
 CN Dizprazol
 CN Dudencer
 CN Elgam
 CN Emeproton
 CN Epirazole
 CN Gastrimut
 CN GastroGard
 CN Gastroloc
 CN Gastrozole
 CN Gibancer
 CN H 168/68
 CN Indurgan
 CN Inhibitron
 CN Inhipump
 CN Logastric
 CN Lomac
 CN Losec
 CN Mepral
 CN Miol
 CN Miracid
 CN Mopral
 CN Ocid
 CN Omapren
 CN Omebeta 20
 CN Omed
 CN Omedar
 CN OMEP
 CN Omepradex
 CN Omepral
 CN Omeprazen
 CN Omeprazole
 CN Omeprazon
 CN Omepril
 CN Omezol
 CN Omezzol
 CN Omid
 CN Omisec
 CN Omizac
 CN OMP

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY

FS 3D CONCORD


DR 172964-80-6, 131959-78-9

MF C17 H19 N3 O3 S

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*,
 IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
 PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)


Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3026 REFERENCES IN FILE CA (1907 TO DATE)
 56 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3036 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 69365-65-7 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Piperidine, 4-(diphenylmethyl)-1-[(octylimino)methyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Fenoctimin
 CN Fenoctimine
 FS 3D CONCORD
 MF C27 H38 N2
 CI COM
 LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, DDFU, DRUGU, EMBASE, SYNTHLINE, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
 10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 50678-27-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN D-Glucopyranose, pentakis(3,4,5-trihydroxybenzoate) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN D-Glucose, pentagallate (7CI)
 OTHER NAMES:
 CN 1,2,3,4,6-Pentagalloyl-D-glucose
 CN CJ 90002
 CN D-Glucose, 1,2,3,4,6-pentagallate
 CN Penta-O-galloyl-D-glucose
 CN Pentagalloylglucose
 FS STEREOSEARCH
 DR 126420-90-4, 147370-08-9, 40410-94-4
 MF C41 H32 O26
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, PHAR,

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



99 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 99 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 4091-50-3 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Benzeneethanamine, 4-methoxy-N-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phenethylamine, p-methoxy-N-methyl- (6CI, 8CI)
 OTHER NAMES:
 CN (p-Methoxyphenethyl)methylamine
 CN 4-Methoxy-N-methylbenzeneethanamine
 CN 4-Methoxy-N-methylphenethylamine
 CN N-(p-Methoxyphenethyl)methylamine
 CN N-Methyl-(p-methoxyphenethyl)amine
 CN N-Methyl-β-(4-methoxyphenyl)ethylamine
 CN N-Methyl-2-(4-methoxyphenyl)ethylamine
 CN N-Methyl-4-methoxy-β-phenethylamine
 CN N-Methyl-4-methoxyphenethylamine
 CN N-Methyl-N-(4-methoxyphenethyl)amine
 CN p-Methoxy-N-methylphenethylamine
 CN [2-(4-Methoxyphenyl)ethyl]methylamine
 FS 3D CONCORD

MF C10 H15 N O
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT,
CAOLD, CAPLUS, CASREACT, CHEMCATS, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, NAPRALERT, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, USPAT2,
USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1151 REFERENCES IN FILE CA (1907 TO DATE)
745 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1151 REFERENCES IN FILE CAPLUS (1907 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN 465-21-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Bufa-20,22-dienolide, 3,14-dihydroxy-, (3 β ,5 β)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 5 β -Bufa-20,22-dienolide, 3 β ,14-dihydroxy- (7CI, 8CI)
CN Bufalin (6CI)

OTHER NAMES:

CN NSC 89595
FS STEREOSEARCH
DR 2381-02-4
MF C24 H34 O4
CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHM,
DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
NAPRALERT, PROMT, RTECS*, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

295 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 296 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 36 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN

RN 154-23-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-,
 (2R,3S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-,
 (2R-trans)-

CN Catechol (8CI)

OTHER NAMES:

CN (+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol

CN (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol

CN (+)-Catechin

CN (+)-Catechol

CN (+)-Cianidanol

CN (+)-Cyanidan-3-ol

CN (+)-Cyanidanol

CN (+)-Cyanidanol-3

CN (2R,3S)-(+)-Catechin

CN 3-Cyanidanol, (+)-

CN Biocatechin

CN Catechin

CN Catechin (flavan)

CN Catechinic acid

CN Catechol (flavan)

CN Catechuic acid

CN Catergen

CN Cianidanol

CN Cyanidanol

CN Cyanidol

CN D-(+)-Catechin

CN D-Catechin

CN d-Catechin

CN D-Catechol


CN Dexcyanidanol

CN NSC 2819

CN Sunkatol No. 1

CN Teafuran 30A
 CN trans-(+)-3,3',4',5,7-Flavanpentol
 FS STEREOSEARCH
 DR 523994-21-0, 321-01-7, 16198-00-8, 4211-28-3, 5323-80-8, 159761-73-6,
 379227-23-3
 MF C15 H14 O6
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES,
 DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT,
 NIOSHTIC, PDLCOM*, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER,
 USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6273 REFERENCES IN FILE CA (1907 TO DATE)
 328 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 6284 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 112-80-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 9-Octadecenoic acid (9Z)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 9-Octadecenoic acid (Z)-
 CN Oleic acid (8CI)
 OTHER NAMES:
 CN Δ⁹-cis-Octadecenoic acid
 CN Δ⁹-cis-Oleic acid
 CN 9-cis-Octadecenoic acid
 CN 9-Octadecenoic acid, (Z)-
 CN 9Z-Octadecenoic acid
 CN cis-Δ⁹-Octadecenoic acid
 CN cis-9-Octadecenoic acid
 CN cis-Oleic acid
 CN D 100
 CN D 100 (fatty acid)
 CN Edenor ATiO5
 CN Edenor FTiO5
 CN Emersol 205
 CN Emersol 211
 CN Emersol 213NF
 CN Emersol 214NF

CN Emersol 233
 CN Emersol 6313NF
 CN Extra Oleic 80R
 CN Extra Oleic 90
 CN Extra Oleic 99
 CN Extra Olein 80
 CN Extra Olein 90R
 CN Extraolein 90
 CN Industrene 105
 CN Lunac O-CA
 CN Lunac O-LL
 CN Lunac O-P
 CN Lunac OA
 CN NAA 35
 CN Neo-Fat 92-04
 CN Oleine 7503
 CN Pamolyn 100
 CN Priolene 6906
 CN Priolene 6907
 CN Priolene 6928
 CN Priolene 6930
 CN Priolene 6933
 CN Vopcolene 27
 CN Wecoline OO
 CN Z-9-Octadecenoic acid
 FS STEREOSEARCH
 DR 8046-01-3, 56833-51-3, 17156-84-2
 MF C18 H34 O2
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB,
 DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2,
 ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB,
 IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*,
 PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USAN,
 USPAT2, USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

45296 REFERENCES IN FILE CA (1907 TO DATE)
 2559 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 45372 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 51-45-6 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Imidazole-4-ethanamine (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Histamine (8CI)
 OTHER NAMES:
 CN β -Imidazolyl-4-ethylamine
 CN 2-(1H-Imidazol-4-yl)ethanamine

CN 2-(1H-Imidazol-4-yl)ethylamine
 CN 2-(1H-Imidazol-5-yl)ethanamine
 CN 2-(1H-Imidazol-5-yl)ethylamine
 CN 2-(4-Imidazolyl)ethanamine
 CN 2-(4-Imidazolyl)ethylamine
 CN 4-(2-Aminoethyl)imidazole
 CN 5-Imidazoleethylamine
 CN Eramin
 CN Ergamine
 CN Ergotidine
 CN Imidazole-4-ethylamine
 CN NSC 33792
 FS 3D CONCORD
 MF C5 H9 N3
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,
 CSNB, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB,
 IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
 NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SCISEARCH, SPECINFO,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

34678 REFERENCES IN FILE CA (1907 TO DATE)
 479 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 34687 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 51-17-2 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Benzimidazole (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Benzimidazole (6CI, 8CI)
 OTHER NAMES:
 CN 1,3-Benzodiazole
 CN 1,3-Diazaindene
 CN 3-Azaindole
 CN Azindole
 CN Benziminazole
 CN Benzoglyoxaline
 CN Benzoimidazole
 CN BZI
 CN N,N'-Methenyl-o-phenylenediamine
 CN NSC 759
 CN o-Benzimidazole
 FS 3D CONCORD
 DR 25463-25-6, 79351-71-6, 116421-27-3
 MF C7 H6 N2
 CI COM, RPS
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,

CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*,
 DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*,
 SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6040 REFERENCES IN FILE CA (1907 TO DATE)
 1881 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 6047 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN

RN 50-78-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(Acetyloxy)benzoic acid

CN 2-Acetoxybenzoic acid

CN 2-Carboxyphenyl acetate

CN A.S.A. Empirin

CN AC 5230

CN Acenterine

CN Acesal

CN Acesan

CN Acetard

CN Aceticyl

CN Acetilum acidulatum

CN Acetisal

CN Acetol

CN Acetonyl

CN Acetophen

CN Acetosol

CN Acetosalic acid

CN Acetosalin

CN Acetylin

CN Acetylsal

CN Acetylsalicylic acid

CN Acetyonyl

CN Acetysal

CN Acidum acetylsalicylicum

CN Acimetten

CN Acisal

CN Acylpyrin

CN Adiro

CN Albyl E

CN ASA

CN Asaflow

CN Asagran

CN Asatard

CN Ascoden 30

CN Ascolong

CN Ascriptin

CN Aspalon
 CN Aspergum
 CN Aspidrops
 CN Aspirin
 CN Aspirin Protect 100
 CN Aspirin Protect 300
 CN Aspirin-Direkt
 CN Aspirina 03
 CN Aspro
 CN Aspro Clear
 CN Aspropharm
 CN Asteric
 CN Bayer
 CN Benaspir

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY


FS 3D CONCORD
 DR 11126-35-5, 11126-37-7, 98201-60-6, 2349-94-2, 26914-13-6
 MF C9 H8 O4
 CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19146 REFERENCES IN FILE CA (1907 TO DATE)
 372 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 19191 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN

RN 50-00-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Formaldehyde (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN BFV
 CN F-gen
 CN Fannoform
 CN Floguard 1015
 CN FM 282
 CN Fordor
 CN Formalin
 CN Formalith
 CN Formic aldehyde
 CN Formol
 CN Fyde
 CN Lysoform
 CN Methaldehyde

CN Methanal
 CN Methyl aldehyde
 CN Methylene oxide
 CN Morbicide
 CN NSC 298885
 CN Oxomethane
 CN Oxymethylene
 CN Paraform
 CN Superlysoform
 FS 3D CONCORD
 DR 8005-38-7, 8006-07-3, 8013-13-6, 112068-71-0
 MF C H2 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB,
 DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2,
 ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB,
 IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA,
 PROMT, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN,
 USPAT2, USPATFULL, VETU, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

H₂C=O

****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

68262 REFERENCES IN FILE CA (1907 TO DATE)
 6511 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 68334 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	33.43	344.33
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 11:27:41 ON 07 SEP 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
 FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 117976-89-3/rn

466 117976-89-3

12 117976-89-3D

L12 457 117976-89-3/RN

(117976-89-3 (NOTL) 117976-89-3D)

=> s 117976-89-3/rn or 103577-45-3/rn or 154644-14-1/rn or 172964-80-6/rn or 131959-78-9/rn

466 117976-89-3

12 117976-89-3D

457 117976-89-3/RN

(117976-89-3 (NOTL) 117976-89-3D)

1251 103577-45-3

17 103577-45-3D

1241 103577-45-3/RN

(103577-45-3 (NOTL) 103577-45-3D)

0 154644-14-1

0 154644-14-1D

0 154644-14-1/RN

(154644-14-1 (NOTL) 154644-14-1D)

0 172964-80-6

0 172964-80-6D

0 172964-80-6/RN

(172964-80-6 (NOTL) 172964-80-6D)

0 131959-78-9

0 131959-78-9D

0 131959-78-9/RN

(131959-78-9 (NOTL) 131959-78-9D)

L13 1434 117976-89-3/RN OR 103577-45-3/RN OR 154644-14-1/RN OR 172964-80-6/RN OR 131959-78-9/RN

=> s l13 and l7

L14 1 L13 AND L7

=> d bib abs hitstr

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:412815 CAPLUS

DN 140:386032

TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor

IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee

PA S. Korea

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRAI KR 2002-67653 A 20021102
 KR 2003-75511 A 20031028

AB The invention discloses a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.

IT 73590-58-6, Omeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 117976-89-3, Rabeprazole
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazolic compound with proton pump inhibitor activity for preventing secretion of IgE-dependent histamine releasing factor)


RN 73590-58-6 CAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102625-70-7 CAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-45-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
 CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> s l13 adn l8
 MISSING OPERATOR L13 ADN
 The search profile that was entered contains terms or
 nested terms that are not separated by a logical operator.

=> s l13 and l8
 L15 2 L13 AND L8

=> d 1-2 bib abs hitstr

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:412815 CAPLUS
 DN 140:386032
 TI Composition using a benzimidazolic compound with proton pump inhibitor
 activity for preventing secretion of immunoglobulin E-dependent histamine
 releasing factor
 IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
 PA S. Korea
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,				
	TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI KR 2002-67653 A 20021102
 KR 2003-75511 A 20031028


AB The invention discloses a composition for inhibiting the secretion of an
 IgE-dependent histamine-releasing factor, and pharmaceutical use
 thereof. The composition of the invention contains a benzimidazolic compound
 having proton pump inhibitor activity as an active ingredient.
 Furthermore, the composition of the invention may contain at least one
 substance selected from the group consisting of fenoctimine, oleic acid,
 catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide
 antibiotic bafilomycin and concanamycin, all having proton pump inhibitor
 activity, as an addnl. active ingredient or a single active ingredient.
 The composition of the invention can be advantageously used as a pharmaceutical
 composition for the prevention and treatment of various allergic

diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.

IT 73590-58-6, Omeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 117976-89-3, Rabeprazole
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazolic compound with proton pump inhibitor activity for preventing secretion of IgE-dependent histamine releasing factor)


RN 73590-58-6 CAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102625-70-7 CAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-45-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 117976-89-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



DN 137:257592
 TI T-cell reactions to drugs in distinct clinical manifestations of drug allergy
 AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
 CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
 SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
 CODEN: JIAIEF; ISSN: 1018-9068
 PB Hogrefe & Huber Publishers
 DT Journal
 LA English
 AB Recent data indicate that T cells play a major role in different forms of drug allergies. To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug allergies. We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific IgE-antibodies were determined. All patients were HLA typed. Clin. manifestations of the drug allergy were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, urticaria, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as urticaria/angioedema. In most cases (63%), β -lactam antibiotics were found to have caused the allergic reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug allergy. A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
 IT 103577-45-3, Agopton
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (T-cell reactions to drugs in distinct clin. manifestations of drug allergy)
 RN 103577-45-3 CAPLUS
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (l13 or l3) and l7
 L16 1 (L13 OR L3) AND L7

=> d bib

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN


AN 2004:412815 CAPLUS
 DN 140:386032
 TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
 IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
 PA S. Korea
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	KR 2002-67653	A	20021102		
	KR 2003-75511	A	20031028		

=> s (l13 or l3) and l8
 L17 4 (L13 OR L3) AND L8


=> d 1-4 bib abs hitstr

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:834661 CAPLUS
 DN 142:348646
 TI Recurrent **anaphylaxis** linked to pantoprazole
 AU Kollmeier, Alexa P.; Eddleston, Jane; Zuraw, Bruce L.; Christiansen, Sandra C.
 CS Department of Asthma, Allergy and Immunol., Scripps Clin., La Jolla, CA, 92037, USA
 SO Journal of Allergy and Clinical Immunology (2004), 114(4), 975-977
 CODEN: JACIBY; ISSN: 0091-6749
 PB Elsevier Inc.
 DT Journal
 LA English
 AB The case of a 47-yr-old man with recurrent **anaphylaxis** induced by pantoprazole, a benzimidazole proton pump inhibitor, is presented. In this patient, the pos. skin test response and increased tryptase level are consistent with prior case reports of proton pump inhibitor **anaphylaxis** and suggest an immediate hypersensitivity mechanism. Although mutations in the CYP2C19 gene were not identified, the timing of anaphylactic events invokes the possible involvement of modifying pharmacogenetic factors, variations in relative levels of drug-specific IgE, or both.
 IT 102625-70-7, Pantoprazole 138786-67-1, Protonix
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (recurrent **anaphylaxis** linked to pantoprazole)
 RN 102625-70-7 CAPLUS
 CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 138786-67-1 CAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:412815 CAPLUS

DN 140:386032

TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor

IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee

PA S. Korea

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI KR 2002-67653	A	20021102		
KR 2003-75511	A	20031028		


AB The invention discloses a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient.

The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.


IT 73590-58-6, Omeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 117976-89-3, Rabeprazole
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazolic compound with proton pump inhibitor activity for preventing secretion of IgE-dependent histamine releasing factor)
 RN 73590-58-6 CAPLUS
 CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102625-70-7 CAPLUS
 CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-45-3 CAPLUS
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
 CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:223222 CAPLUS
 DN 137:257592
 TI T-cell reactions to drugs in distinct clinical manifestations of drug allergy
 AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
 CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
 SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
 CODEN: JIAIEF; ISSN: 1018-9068
 PB Hogrefe & Huber Publishers
 DT Journal
 LA English
 AB Recent data indicate that T cells play a major role in different forms of drug allergies. To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug allergies. We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific IgE-antibodies were determined. All patients were HLA typed. Clin. manifestations of the drug allergy were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, urticaria, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as urticaria/angioedema. In most cases (63%), β -lactam antibiotics were found to have caused the allergic reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug allergy. A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
 IT 103577-45-3, Agopton
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (T-cell reactions to drugs in distinct clin. manifestations of drug allergy)
 RN 103577-45-3 CAPLUS
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:125206 CAPLUS
 DN 137:210620
 TI TU-572, a Potent and Selective CD45 Inhibitor, Suppresses IgE-Mediated Anaphylaxis and Murine Contact Hypersensitivity

Reactions

AU Hamaguchi, Takuya; Takahashi, Akiko; Manaka, Akira; Sato, Masakazu; Osada, Hiroyuki

CS Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Japan

SO International Archives of Allergy and Immunology (2001), 126(4), 318-324
CODEN: IAAIEG; ISSN: 1018-2438

PB S. Karger AG

DT Journal


LA English

AB Background: CD45, receptor-type protein tyrosine phosphatases (PTPases) are essential components of signaling through both the T cell receptor and the B cell antigen receptor. However, the functional significance of CD45 in the signaling pathway through the high-affinity Ig (Ig) E receptor has not yet been established. In this study, we demonstrate that the potent CD45 inhibitor neg. regulates **IgE-dependent anaphylaxis** and contact hypersensitivity reactions. Method: We have previously found that TU-572, 2-[[4-methylthiopyridin-2-yl)methylsulfinyl]-5-isopropoxybenzimidazole, had a potent and selective inhibitory effect against PTPase activity of CD45. Using a CD45 inhibitor, we examined in vitro and in vivo **IgE-mediated** responses. Results: TU-572 potently inhibited histamine release from rat peritoneal mast cells and mouse systemic **anaphylaxis** reaction using monoclonal anti-dinitrophenyl (DNP) **IgE** and DNP-BSA. TU-572 also suppressed the immediate-type hypersensitivity response induced by repeated epicutaneous application of trinitrochlorobenzene in BALB/c mice. Conclusion: These findings revealed that the PTPase activity of CD45 played a critical role in signal transduction of **IgE-mediated anaphylaxis** in vitro and in vivo. PTPase inhibitors such as TU-572 are useful in the treatment of **allergic diseases**.

IT 326592-39-6, TU 572
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TU-572, a potent and selective CD45 inhibitor, suppresses **IgE-mediated anaphylaxis** and murine contact hypersensitivity reactions)

RN 326592-39-6 CAPLUS

CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	61.96	406.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-5.11	-8.76

STN INTERNATIONAL LOGOFF AT 11:32:39 ON 07 SEP 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxgl614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:41:52 ON 14 APR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:42:16 ON 14 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2006 HIGHEST RN 880252-04-0

DICTIONARY FILE UPDATES: 12 APR 2006 HIGHEST RN 880252-04-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UG/regprops.html>

=> s 326592-39-6/rn

L1 1 326592-39-6/RN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 326592-39-6 REGISTRY
 ED Entered STN: 11 Mar 2001
 CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN TU 572
 FS 3D CONCORD
 MF C17 H19 N3 O2 S2
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, PROUSDDR, SYNTHLINE



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s omeprazole
 L2 23 OMEPRAZOLE

=> d

L2 ANSWER 1 OF 23 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 755036-61-4 REGISTRY
 ED Entered STN: 01 Oct 2004
 CN 1H-Benzimidazole, 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, hydrate (2:3) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN **S-Omeprazole sesquihydrate**
 FS STEREOSEARCH
 MF C17 H19 N3 O3 S . 3/2 H2 O
 SR CA
 LC STN Files: CA, CAPLUS
 CRN (119141-88-7)

Absolute stereochemistry. Rotation (-).



● 3/2 H₂O

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s lansoprazole
L3 18 LANSOPRAZOLE

=> d


L3 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2006 ACS on STN
RN 482370-08-1 REGISTRY
ED Entered STN: 28 Jan 2003
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-, mixt. with 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Lansoprazole-amoxicillin mixt.**
FS STEREOSEARCH
MF C16 H19 N3 O5 S . C16 H14 F3 N3 O2 S
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 103577-45-3
CMF C16 H14 F3 N3 O2 S



CM 2

CRN 26787-78-0
CMF C16 H19 N3 O5 S

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s pantoprazole
L4 26 PANTOPRAZOLE

=> d

L4 ANSWER 1 OF 26 REGISTRY COPYRIGHT 2006 ACS on STN
RN 867300-65-0 REGISTRY
ED Entered STN: 11 Nov 2005

CN 1H-Benzimidazol-5-ol, 6-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 6-Hydroxy-pantoprazole thioether

FS 3D CONCORD

MF C16 H15 F2 N3 O4 S

SR CA

LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s rabeprazole

L5 6 RABEPRAZOLE

=> d

L5 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN

RN 226904-99-0 REGISTRY

ED Entered STN: 01 Jul 1999

CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, calcium salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Rabeprazole calcium


DR 858585-57-6

MF C18 H21 N3 O3 S . 1/2 Ca

SR CA

LC STN Files: CA, CAPLUS, IMSPATENTS

CRN (117976-89-3)



● 1/2 Ca

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.74

30.95

STN INTERNATIONAL LOGOFF AT 10:45:16 ON 14 APR 2006